Andrew M. Kaz
Associate Professor
Medicine
Division of Gastroenterology

Faculty Information

Biography

Andrew Kaz, M.D., is a board certified gastroenterologist at the Puget Sound VA Medical Center and a UW assistant professor of Medicine and Gastroenterology.

Dr. Kaz strives to treat each patient exactly as he would treat a member of his own family.

Dr. Kaz earned his M.D. at Duke. His professional interests include molecular alterations in Barrett’s esophagus and colon cancer and colon cancer screening.

Board Certifications:

  • Gastroenterology, 2007, American Board of Internal Medicine
Education & Training: 
Fellowship in Gastroenterology
University of Washington
Residency in General Internal Medicine
University of Michigan Medical Center
Internship in General Internal Medicine
University of Michigan Medical Center
Medical Education
Duke University School of Medicine
1999
Research & Clinical Interests
Clinical Interests: 
  • Gastroenterology (Digestive)
  • Internal Medicine
Publications
Publications: 
JA Cohn, TD Nguyen, AM Kaz, J Kole (1994). The cystic fibrosis transmembrane conductance regulator in rat enterocytes. Pediatric Pulmonology 10: 189-190. [original work]
 
LD Howell, R Borchardt, J Kole, AM Kaz, C Randak, JA Cohn (2004). Protein kinase A regulates ATP hydrolysis and dimerization by CFTR (cystic fibrosis transmembrane conductance regulator) domain. Biochem. J. 378: 151-159. PMID: 14602047. [original work]
 
P Sonveaux*, AM Kaz*, SA Snyder, RA Richardson, LI Cardenas-Navia, RD Braun, JR Pawloski, GM Tozer, J Bonaventura, TJ McMahon, JS Stamler, MW Dewhirst (2005). Oxygen regulation of tumor perfusion by S-nitrosohemoglobin reveals a pressor activity of nitric oxide. Circulation Research 96:1119-1126. PMID:15879309 (*co-first authors). [original work]
 
F Kesisoglou, JR Chamberlain, P Schmiedlin-Ren, A Kaz, D Fleisher, B Roessler, and EM Zimmermann. (2005) Chimeric Ad5 vectors expressing the short fiber of Ad41 show reduced affinity for human intestinal epithelium. Molecular Pharmaceutics 2(6):502-8. PMID:16323957 [original work]
 
*A Kaz and T Brentnall. (2006) Genetic testing for colon cancer. Nature Clinical Gastroenterology and Hepatology 3(12):670-9. PMID:17130877 [review]
 
*A Kaz, Y-H Kim, S Dzieciatkowski, H Lynch, P Watson, MK Washington, L Lin, W Grady. (2007) Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch Syndrome adenomas. International Journal of Cancer 120, 1922-1929. PMID:17278092 [original work]
 
W Grady, R Parkin, P Mitchell, J Lee, Y-H Kim, K Tsuchiya1, M Washington, C Paraskeva, J Willson, A Kaz, E Kroh, A Allen, B Fritz, S Markowitz, M Tewari. (2008) Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer . Oncogene 27(27):3880-8. PMID:18264139 [original work]
 
*AM Kaz, C Wong, Y Luo, JB Virgin, MK Washington, JE Willis, RS Leidner, A Chak, WM Grady (2011). DNA methylation profiling in Barrett’s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics 6(12):1403-12. PMID:22139570 [original work]
 
AM Kaz, Y Luo, S Dzieciatkowski, A Chak, JE Willis, MP Upton, RS Leidner, WM Grady (2012). Aberrantly methylated PKP1 in the progression of Barrett’s esophagus to esophageal adenocarcinoma. Genes, Chromosomes, and Cancer: Apr;5(4):384-93. PMID: 22170739 [original work]
 
A Kaz and WM Grady (2012). Epigenetic Biomarkers in Esophageal Cancer. Cancer Letters: 342(2):193-199; PMID:22406828 [review]
 
Y Luo, AM Kaz, S Kanngurn, P Welsch, SM Morris, J Wang, JD Lutterbaugh, SD Markowitz, WM Grady (2013). NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer. PLoS Genetics 9(7):1-14. PMID: 23874207 [original work]
 
*AM Kaz, C Wong, S Dzieciatkowski, Y Luo, RE Schoen, WM Grady (2014). Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age. Epigenetics Jan 10;9(4). PMID:24413027 [original work]
 
Luo Y, Wong C-J, Kaz AM, Dzieciatkowski S, Carter KT, Morris SM, Wang J,Willis JE, Makar KW, Ulrich CM, Lutterbaugh JD, Shrubsole MJ, Zheng W, Markowitz SD, Grady WM (2014). Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology 147(2):418-29. PMID:24793120 [original work]
 
AM Kaz, A Bass, M Stachler, W Grady (2015). Genetic and Epigenetic Alterations in Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastroenterology Clinics of North America 44: 473–489. PMID:26021206 [review]
 
Yu M, O'Leary RM, Kaz AM, Morris SM, Carter KT, Chak A, Chandar A, Willis JE, Moinova HR, Markowitz SD, Brenner DE, Anandabapasathy S, Westerhoff M, Wong C, Shaheen NJ, Chen Y, Barnholtz-Sloan JS, Grady WM (2015). Methylated B3GAT2 and ZNF793 are potential detection biomarkers for Barrett's esophagus. Cancer Epidemiology, Biomarkers & Prevention 24(12):1890-7. PMID:26545406 [original work]
 
Kaz AM, Anwar A, Robinson-O’Neill D, Dominitz JA (2016). Use of a novel polyp "ruler snare" improves estimation of colon polyp size. Gastrointestinal Endoscopy, 83(4), 812-816. PMID:26382052 [original work]
 
Vindigni S, Kaz AM (2016). Universal Screening of Colorectal Cancers for Lynch Syndrome: Challenges and Opportunities. Digestive Diseases and Sciences, 61(4), 969-976. PMID:26602911 [review]
 
Parang B, Kaz AM, Barrett CW, Short SP, Keating C, Mittal MK, Naik R, Washington MK, Revetta F, Smith JJ, Chen X, Brand T, Bader DM, Tansey WP, Chen R, Brentnall T, Grady WM, Williams CS (2017). BVES regulates c-myc stability via PP2A and suppresses colitis-induced tumorigenesis. Gut, 66(5):852-862. PMID:28389570. [original work]
 
Cui J, Cai Y, Hu Y, Huang Z, Luo Y, Kaz AM, Yang Z, Chen D, Fan X, Grady WM, Wang J. Epigenetic silencing of TMP2 contributes to colorectal cancer progression upon RhoA activation (2016). Tumor Biology, Jun 23 (Epub ahead of print). PMID: 27333992 [original work]
 
Curtius K, Wong C, Kaz AM, Hazelton W, Chak A, Willis JE, Grady WM, Luebeck G (2016). A molecular clock infers heterogeneous tissue age among patients with Barrett’s esophagus. PLOS Computation Biology, 2016 May 11;12(5). PMID:27168458. [collaboration]
 
Knight J, Kim E, Ivanov I, Davidson L, Goldsby J, Hullar M, Randolph T, Kaz A, Levy L, Lampe J, Chapkin R (2016). Comprehensive site-specific whole
genome profiling of stromal and epithelial colonic gene signatures in human sigmoid colon and rectal tissue. Physiological Genomics, 2016 Sep 1;48(9):651-9 PMID:27401218. [original work]
 
Kaz AM, Wong C, Varadan V, Willis JE, Chak A, Grady WM (2016). Global DNA methylation patterns in Barrett’s esophagus, dysplastic Barrett’s, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use. Clinical Epigenetic, 8(1),1-16. [original work]
 
Roberts JR, Siekas LL, Kaz AM (2016). Anal intraepithelial neoplasia: a review of diagnosis and management. World J of Gastrointestinal Oncology, 9(2),50-61. [review]
 
Dominitz JA, Robertson DJ, Ahnen DJ et al and the CONFIRM study group (2017). Colonoscopy vs. fecal immunochemical test in reducing mortality from colorectal cancer (CONFIRM): rationale for study design. American Journal of Gastroenterology, 10 October 2017. [collaboration].
 
Yu M, Maden S, Stachler M, Kaz AM, Ayers J, Guo Y, Carter KT, Willbanks, A, Heinzerling TJ, O’Leary RM, Xu Xinsen, Bass A, Chandar A, Chak A, Elliot R, Willis JE, Markowitz SD, Grady WM (2019). Subtypes of Barrett’s esophagus and esophageal adenocarcinoma based on genome-wide methylation analysis. Gut 68:389-399. [original work].
 
Kaz AM, Rhodes CT, Lin S, Huang SA, Wong C, Sandstrom RS, Wang Y, Chak A, Willis JE, Grady WM, Lin CA (2017). Case report of molecular signature in poorly differentiated esophageal adenocarcinoma (2017). Cancer Research Frontiers, 3(1):170-191 [original research].
 
Lampe JW, Kim E, Levy L, Davidson LA, Goldsby JS, Miles FL, Navarro SL, Randolph TW, Zhao N, Ivanov I, Kaz AM, Damman C, Hockenbery DM, Hullar MAJ, Chapkin RS. Colonic mucosal and exfoliome transcriptomic profiling and fecal microbiome response to a flaxseed lignin extract intervention in humans (2019). The American Journal of Clinical Nutrition, 110:377-90 [original research].
 
Luebeck EG, Hazelton WD, Curtius K, Maden SK, Yu M, Carter KT, Burke W, Lampe PD, Li CI, Ulrich CM, Newcomb PA, Westerhoff M, Kaz AM, Luo Y, Inadomi JM, Grady WM (2019). Implications of epigenetic drift in colorectal neoplasia. Cancer Research 1;79(3):495-504 [original work].
 
Spechler SJ, Hunter JG, Jones KM…Kaz AM…Huang GD (2019). Randomized trial of medical vs. surgical treatment for refractory heartburn. The New England Journal of Medicine, 381(16): 1513-23. [original research].
 
Snider EJ, Kaz AM, Inadomi JM, Grady WM (2020). Chemoprevention of Esophageal Adenocarcinoma in Barrett’s Esophagus. Gastroenterology Report (accepted for publication) [review].